HOMER1 and breast carcinoma: This discrepancy may be addressed by evaluating additional cell line models for both prostate and breast cancer to understand if unique genomic or epigenetic factors (e.g., loss of promoter methylation) drive HOMER1 expression and contribute to therapy resistance.